Brigatinib in Patients With Anaplastic Lymphoma
Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002), NCT03535740
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
The primary purpose of this study is to determine the efficacy of brigatinib by confirmed objective response rate (ORR) by response evaluation criteria in solid tumors (Response Evaluation Criteria in Solid Tumors [RECIST]), in participants with ALK+ locally advanced or metastatic NSCLC whose disease has progressed on therapy with alectinib or ceritinib.
MORE DETAILS ON THIS TRIAL:
18076 / NCT03535740 / Open 6-17-2019 / STAR /
TRIAL AVAILABLE AT THESE LOCATIONS